长春高新子公司两药品临床试验申请获得批准

Core Viewpoint - Changchun High-tech has received approval for clinical trials of two new drugs developed by its subsidiary, Changchun Jinsai Pharmaceutical, indicating a significant step in its strategic focus on innovative pharmaceutical products [1][2]. Group 1: Drug Approvals - Changchun Jinsai Pharmaceutical has obtained the "Drug Clinical Trial Approval Notification" from the National Medical Products Administration for GS3-007a, an oral small molecule growth hormone secretagogue aimed at treating children with growth hormone deficiency [2]. - The company also received approval for the clinical trial of GenSci140, a targeted antibody-drug conjugate for treating locally advanced or metastatic solid tumors [1]. Group 2: Business Strategy and R&D Investment - Changchun High-tech's main business includes the R&D, production, and sales of biopharmaceuticals and traditional Chinese medicine, with a focus on gene engineering, biological vaccines, antibody drugs, high-end chemical drugs, and modern Chinese medicine [1]. - In the first three quarters, the company increased its R&D investment by 22.96% year-on-year, reaching 1.733 billion yuan, which reflects its commitment to innovation and transformation into a global pharmaceutical company [1]. Group 3: Market Position and Future Prospects - The approval of GS3-007a is particularly significant as there are currently no similar products available in the domestic market, which could address unmet clinical needs and enhance the company's competitive edge [2]. - The successful progression of clinical trials for these products could broaden the company's business scope and optimize its product structure, aligning with its strategic focus on children's growth and development [2].